

Marilyn Martinez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4556077/publications.pdf>

Version: 2024-02-01

74
papers

2,252
citations

279798

23
h-index

223800

46
g-index

78
all docs

78
docs citations

78
times ranked

2392
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of gastrointestinal differences in veterinary species on the oral drug solubility, in vivo dissolution, and formulation of veterinary therapeutics. <i>ADMET and DMPK</i> , 2022, 10, 1-25.	2.1	5
2	A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption. <i>AAPS Journal</i> , 2022, 24, 60.	4.4	5
3	A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development. <i>AAPS Journal</i> , 2022, 24, 61.	4.4	2
4	An introduction to the JVPT special issue on antimicrobial drugs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2021, 44, 133-136.	1.3	0
5	Evaluation of partial area under the curve in bioequivalence studies using destructive sampling design. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2021, 44, 628-643.	1.3	1
6	Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics. <i>AAPS Journal</i> , 2021, 23, 59.	4.4	12
7	The publication of studies involving the use of human critically important antimicrobial agents in veterinary species. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2021, 44, 986-989.	1.3	0
8	Expert Discussion of the Role of Rate Constant Versus Clearance Approaches to Define Drug Pharmacokinetics: Theoretical and Clinical Considerations. <i>AAPS Journal</i> , 2020, 22, 25.	4.4	0
9	The Impact of Infection and Inflammation on Drug Metabolism, Active Transport, and Systemic Drug Concentrations in Veterinary Species. <i>Drug Metabolism and Disposition</i> , 2020, 48, 631-644.	3.3	9
10	Considerations in the extrapolation of drug toxicity between humans and dogs. <i>Current Opinion in Toxicology</i> , 2020, 23-24, 98-105.	5.0	3
11	Reconciling Human-Canine Differences in Oral Bioavailability: Looking beyond the Biopharmaceutics Classification System. <i>AAPS Journal</i> , 2019, 21, 99.	4.4	8
12	Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 141, 191-209.	4.3	6
13	Impact of bovine respiratory disease on the pharmacokinetics of danofloxacin and tulathromycin in different ages of calves. <i>PLoS ONE</i> , 2019, 14, e0218864.	2.5	13
14	Questions associated with the development of novel drugs intended for the treatment of bacterial infections in veterinary species. <i>Veterinary Journal</i> , 2019, 248, 79-85.	1.7	3
15	Primer on the Science of In Vitro Dissolution Testing of Oral Dosage Forms and Factors Influencing its Biological Relevance. <i>Dissolution Technologies</i> , 2019, 26, 14-26.	0.6	0
16	Formulation characteristics and in vitro release testing of cyclosporine ophthalmic ointments. <i>International Journal of Pharmaceutics</i> , 2018, 544, 254-264.	5.2	15
17	Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2018, 41, 171-183.	1.3	67
18	Effect of age on the pharmacokinetics and distribution of tulathromycin in interstitial and pulmonary epithelial lining fluid in healthy calves. <i>American Journal of Veterinary Research</i> , 2018, 79, 1193-1203.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Effect of age on plasma protein binding of several veterinary drugs in dairy calves 2. Research in Veterinary Science, 2018, 121, 59-64.	1.9	9
20	Population variability in animal health: Influence on doseâ€œexposureâ€œresponse relationships: Part <sc>II</sc>: Modelling and simulation. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, E68-E76.	1.3	10
21	A Simple Approach for Comparing the In Vitro Dissolution Profiles of Highly Variable Drug Products: a Proposal. AAPS Journal, 2018, 20, 78.	4.4	5
22	Population variability in animal health: Influence on doseâ€œexposureâ€œresponse relationships: Part I: Drug metabolism and transporter systems. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, E57-E67.	1.3	20
23	Impact of <sc>ABCB</sc> 1 genotype in Collies on the pharmacokinetics of Râ€œand Sâ€œexofenadine. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 805-814.	1.3	1
24	Exploring Canine-Human Differences in Product Performance. Part II: Use of Modeling and Simulation to Explore the Impact of Formulation on Ciprofloxacin In Vivo Absorption and Dissolution in Dogs. AAPS Journal, 2017, 19, 712-726.	4.4	4
25	Proposed method for estimating clinical cut-off (CO CL) values: An attempt to address challenges encountered when setting clinical breakpoints for veterinary antimicrobial agents. Veterinary Journal, 2017, 228, 33-37.	1.7	14
26	Pharmacokinetics and distribution in interstitial and pulmonary epithelial lining fluid of danofloxacin in ruminant and preruminant calves. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, 179-191.	1.3	11
27	What Does It â€œMeanâ€œ? A Review of Interpreting and Calculating Different Types of Means and Standard Deviations. Pharmaceutics, 2017, 9, 14.	4.5	38
28	When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?. Drug Metabolism and Disposition, 2016, 44, 1934-1939.	3.3	35
29	Use of Modeling and Simulation Tools for Understanding the Impact of Formulation on the Absorption of a Low Solubility Compound: Ciprofloxacin. AAPS Journal, 2016, 18, 886-897.	4.4	9
30	Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid. Journal of Pharmaceutical Sciences, 2016, 105, 3243-3255.	3.3	23
31	Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought Process. AAPS Journal, 2016, 18, 1144-1158.	4.4	15
32	Evaluating In Vivo-In Vitro Correlation Using a Bayesian Approach. AAPS Journal, 2016, 18, 619-634.	4.4	8
33	Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls. AAPS Journal, 2015, 17, 948-964.	4.4	87
34	Demonstrating Comparative In Vitro Bioequivalence for Animal Drug Products Through Chemistry and Manufacturing Controls and Physicochemical Characterization: A Proposal. AAPS Journal, 2015, 17, 307-312.	4.4	2
35	Quality-by-Design III: Application of Near-Infrared Spectroscopy to Monitor Roller Compaction In-process and Product Quality Attributes of Immediate Release Tablets. AAPS PharmSciTech, 2015, 16, 202-216.	3.3	13
36	Canine gastrointestinal physiology: Breeds variations that can influence drug absorption. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 192-203.	4.3	16

#	ARTICLE	IF	CITATIONS
37	Influence of ABCB1 Genotype in Collies on the Pharmacokinetics and Pharmacodynamics of Loperamide in a Dose-Escalation Study. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1392-1407.	3.3	6
38	Workshop report: The 2012 Antimicrobial Agents in Veterinary Medicine: exploring the consequences of antimicrobial drug use: a 3<sup>sc>“” approach. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2014, 37, e1-e16.	1.3	12
39	The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 3377-3397.	3.3	60
40	Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. <i>Drug Metabolism Reviews</i> , 2013, 45, 218-230.	3.6	51
41	Quality by Design and the Development of Solid Oral Dosage Forms. <i>Advances in Delivery Science and Technology</i> , 2013, , 107-129.	0.4	2
42	Dosing Regimen Matters: the Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic/Pharmacodynamic Target. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2795-2805.	3.2	173
43	Regulatory Issues and Challenges Associated with the Development of Performance Specifications for Modified Release Parenteral Products. , 2012, , 505-535.		1
44	Role of the cytochrome P450 enzyme system in veterinary pharmacokinetics: where are we now? Where are we going?. <i>Future Medicinal Chemistry</i> , 2011, 3, 855-879.	2.3	27
45	Patient variation in veterinary medicine - Part II - Influence of physiological variables. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2011, 34, 209-223.	1.3	24
46	The 2010 AAVPT/EAVPT/ECVPT bioequivalence workshop. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2011, 34, 105-107.	1.3	3
47	Factors Influencing the Use and Interpretation of Animal Models in the Development of Parenteral Drug Delivery Systems. <i>AAPS Journal</i> , 2011, 13, 632-649.	4.4	42
48	Welcome to the animal pharmaceuticals special focus. <i>Future Medicinal Chemistry</i> , 2011, 3, 845-846.	2.3	2
49	Breakout session summary from AAPS/CRS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained release products. <i>Journal of Controlled Release</i> , 2010, 142, 2-7.	9.9	48
50	Terminology Challenges: Defining Modified Release Dosage Forms in Veterinary Medicine. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3281-3290.	3.3	7
51	Patient variation in veterinary medicine: part I. Influence of altered physiological states. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2010, 33, 213-226.	1.3	44
52	Current challenges facing the determination of product bioequivalence in veterinary medicine. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2010, 33, 418-433.	1.3	12
53	Antimicrobial Drug Resistance. <i>Handbook of Experimental Pharmacology</i> , 2010, , 227-264.	1.8	27
54	Factors Influencing the Gastric Residence of Dosage Forms in Dogs. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 844-860.	3.3	45

#	ARTICLE	IF	CITATIONS
55	Allometric scaling of clearance in dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2009, 32, 411-416.	1.3	20
56	Pharmacogenetic and Metabolic Differences Between Dog Breeds: Their Impact on Canine Medicine and the Use of the Dog as a Preclinical Animal Model. <i>AAPS Journal</i> , 2008, 10, 110-119.	4.4	83
57	The pharmacogenomics of P-glycoprotein and its role in veterinary medicine. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2008, 31, 285-300.	1.3	55
58	AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor?. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1185-1188.	3.0	70
59	2007 highlights of advances in the pharmaceutical sciences: An American Association of Pharmaceutical Scientists (AAPS) perspective. <i>AAPS Journal</i> , 2007, 9, E219-E226.	4.4	0
60	Comparison of bovine in vivo bioavailability of two sulfamethazine oral boluses exhibiting different in vitro dissolution profiles. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2006, 29, 459-467.	1.3	4
61	Interspecies allometric scaling. Part I: prediction of clearance in large animals. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2006, 29, 415-423.	1.3	53
62	Interspecies allometric scaling: prediction of clearance in large animal species: Part II: mathematical considerations. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2006, 29, 425-432.	1.3	33
63	Challenges and issues in veterinary pharmacology and animal health 2004—Preface. <i>AAPS Journal</i> , 2005, 7, E266-E271.	4.4	0
64	American Academy of Veterinary Pharmacology and Therapeutics 14th Biennial Symposium. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2005, 28, 495-498.	1.3	0
65	A SAS/IML program for simulating pharmacokinetic data. <i>Computer Methods and Programs in Biomedicine</i> , 2005, 78, 39-60.	4.7	3
66	A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 620-643.	2.0	492
67	A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered-dose inhalers. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 110, 713-720.	2.9	31
68	Applying the Biopharmaceutics Classification System to veterinary pharmaceutical products Part I: Biopharmaceutics and formulation considerations. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 805-824.	13.7	58
69	Applying the biopharmaceutics classification system to veterinary pharmaceutical products Part II. Physiological considerations. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 825-850.	13.7	97
70	Modified release drug delivery in veterinary medicine. <i>Drug Discovery Today</i> , 2002, 7, 823-829.	6.4	20
71	Challenges associated with the evaluation of veterinary product bioequivalence: an AAVPT perspective. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2002, 25, 201-220.	1.3	8
72	Response to criticisms of the US FDA parametric approach for withdrawal time estimation: rebuttal and comparison to the nonparametric method proposed by Concordet and Toutain. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2000, 23, 21-35.	1.3	19

#	ARTICLE	IF	CITATIONS
73	Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF). Pharmaceutical Research, 1991, 08, 512-517.	3.5	24
74	Bioequivalence of Generic Thioridazine Drug Productsâ€™The FDA Viewpoint. Drug Intelligence & Clinical Pharmacy, 1987, 21, 362-369.	0.4	6